CANbridge Life Sciences Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Beijing China (2012)

Organization Overview

First Clinical Trial
2016
NCT02853565
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

CANbridge Life Sciences Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

can008 (2 trials)

Drugs in Phase 1 Trials (1)

can106 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2